US2006035833A1PendingUtilityA1

Anti-angiogenic compositions and methods of use

67
Assignee: HUNTER WILLIAM LPriority: Jul 19, 1993Filed: Aug 19, 2005Published: Feb 16, 2006
Est. expiryJul 19, 2013(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay MachanA. Arsenault
A61K 33/24A61K 47/50A61K 31/335C08L 2203/02A61K 45/06A61K 9/0019A61K 47/34A61K 9/1647A61K 31/337A61K 9/167A61K 31/57A61L 2300/416A61L 2430/36A61K 9/7007C08L 67/04C08L 23/0815A61K 47/32A61K 31/185A61L 2300/606A61K 9/1658A61K 31/203A61K 31/136A61L 31/145A61K 9/1635A61L 31/10C07K 14/811A61K 31/122C08L 2312/00C08L 23/0853A61L 31/16A61K 31/519A61K 47/6925A61K 9/5153A61L 2300/622
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims

exact text as granted — not AI-modified
1 . A composition comprising: 
 (a) an anti-angiogenic factor; and    (b) a polymeric carrier.    
     
     
         2 . The composition of  claim 1 , wherein said anti-angiogenic factor is Anti-Invasive Factor.  
     
     
         3 . The composition of  claim 1 , wherein said anti-angiogenic factor is retinoic acid and derivatives thereof.  
     
     
         4 . The composition of  claim 1 , wherein said anti-angiogenic factor is selected from the group consisting of Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1 and Plasminogen Activator Inhibitor-2.  
     
     
         5 . A composition comprising: 
 (a) taxol; and    (b) a polymeric carrier.    
     
     
         6 . The composition of  claim 1 , wherein said composition has an average size of 15 to 200 lm.  
     
     
         7 . The composition of  claim 1 , wherein said polymeric carrier is poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate.  
     
     
         8 . The composition of  claim 1 , wherein said polymeric carrier is poly(lactic-co-glycolic acid).  
     
     
         9 . The composition of  claim 1 , wherein said polymeric carrier is polycaprolactone.  
     
     
         10 . The composition of  claim 1 , wherein said polymeric carrier is polylactic acid.  
     
     
         11 . The composition of  claim 1 , wherein said polymeric carrier is a copolymer of poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate, and polylactic acid.  
     
     
         12 . The composition of  claim 1 , wherein said polymeric carrier is a copolymer of polylactic acid and polycaprolactone.  
     
     
         13 . A method for embolizing a blood vessel, comprising delivering into said vessel a therapeutically effective amount of composition according to claims  1 - 12 , such that said blood vessel is effectively occluded.  
     
     
         14 . The method  claim 13  wherein said blood vessel nourishes a tumor.  
     
     
         15 . A stent, comprising a generally tubular structure, the surface of which is coated with a composition according to claims  1 - 12 .  
     
     
         16 . A method for expanding the lumen of a body passageway, comprising inserting a stent into the passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims  1 - 12 , such that said passageway is expanded.  
     
     
         17 . A method for eliminating vascular obstructions, comprising inserting a vascular stent into a vascular passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims  1 - 12 , such that said vascular obstruction is eliminated.  
     
     
         18 . A method for eliminating biliary obstructions, comprising inserting a biliary stent into a biliary passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims  1 - 12 , such that said biliary obstruction is eliminated.  
     
     
         19 . A method for eliminating urethral obstructions, comprising inserting a urethral stent into a urethra, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims  1 - 12 , such that said urethral obstruction is eliminated.  
     
     
         20 . A method for eliminating esophageal obstructions, comprising inserting an esophageal stent into an esophagus, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims  1 - 12 , such that said esophageal obstruction is eliminated.  
     
     
         21 . A method for eliminating tracheal/bronchial obstructions, comprising inserting a tracheal/bronchial stent into the trachea or bronchi, the stent having a generally tubular structure, the surface of which is coated with a composition according to claims  1 - 12 , such that said tracheal/bronchial obstruction is eliminated.  
     
     
         22 . A method for treating a tumor excision site, comprising administering a composition according to claims  1 - 12  to the resection margin of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at said site is inhibited.  
     
     
         23 . A method for treating corneal neovascularization, comprising administering a therapeutically effective amount of a composition according to claims  1 - 12  to the cornea, such that the formation of blood vessels is inhibited.  
     
     
         24 . The method of  claim 23 , wherein said composition further comprises a topical corticosteroid.  
     
     
         25 . A method for inhibiting angiogenesis in patients with non-tumorigenic, angiogenesis-dependent diseases, comprising administering a therapeutically effective amount of a composition comprising taxol to a patient with a non-tumorigenic angiogenesis-dependent disease, such that the formation of new blood vessels is inhibited.  
     
     
         26 . A method for embolizing a blood vessel in a non-tumorigenic, angiogenesis-dependent diseases, comprising delivering to said vessel a therapeutically effective amount of a composition comprising taxol, such that said blood vessel is effectively occluded.  
     
     
         27 . A method for expanding the lumen of a body passageway, comprising inserting a stent into the passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said passageway is expanded.  
     
     
         28 . A method for eliminating vascular obstructions, comprising inserting a vascular stent into a vascular passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said vascular obstruction is eliminated.  
     
     
         29 . A method for eliminating biliary obstructions, comprising inserting a biliary stent into a biliary passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said biliary obstruction is eliminated.  
     
     
         30 . A method for eliminating urethral obstructions, comprising inserting a urethral stent into a urethra, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said urethral obstruction is eliminated.  
     
     
         31 . A method for eliminating esophageal obstructions, comprising inserting an esophageal stent into an esophagus, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said esophageal obstruction is eliminated.  
     
     
         32 . A method for eliminating tracheal/bronchial obstructions, comprising inserting a tracheal/bronchial stent into the trachea or bronchi, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said tracheal/bronchial obstruction is eliminated.  
     
     
         33 . A method for treating a tumor excision site, comprising administering a composition comprising taxol to the resection margin of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at said site is inhibited.  
     
     
         34 . A method for treating corneal neovascularization, comprising administering a therapeutically effective amount of a composition comprising taxol to the cornea, such that the formation of new vessels is inhibited.  
     
     
         35 . A pharmaceutical product, comprising: 
 (a) taxol, in a container; and    (b) a notice associated with said container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by said agency of said taxol, for human or veterinary administration to treat non-tumorigenic angiogenesis-dependent diseases.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.